Complete colorblindness (achromatopsia) is caused by autosomal recessively inherited mutations in the retinal phototransduction pathway, predominantly in the CNGA3- and CNGB3-subunit of the cyclic nucleotide-gated (CNG) channels in cone photoreceptors. CNGA3, which is mutated in about 25% of the achromatopsia patients, mainly harbors missense mutations which frequently impair the folding and/or trafficking of the mutant CNGA3-channels \[[@B1]\].

Pharmacological chaperones stabilizing the folding of the mutant protein may be used to overcome this folding-/trafficking-deficiency. More than 50 compounds were evaluated in their ability to restore signal transduction using a calcium imaging-based bioassay utilizing the CNGA3-mutant E228K \[[@B2]\]. With this data we created several pharmacophore models using Schrödinger Phase \[[@B3]\], which describe the chemical features of potential pharmacological chaperones targeting achromatopsia.

We used several approaches leading to different pharmacophore hypotheses:

a\) Training with the complete set of experimental data (see Figure [1](#F1){ref-type="fig"})

b\) Training with only dihydropyridines since this group showed the highest experimental activity, and

c\) Training with a data set excluding dihydropyridines.
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Our in-house database TueScreen, which includes ZINC12 \[[@B4]\], was screened to identify potentially active compounds. As a result, several potential molecule classes could be found that may be useful as pharmacological chaperones to improve folding/trafficking of mutant CNG-channels. We will experimentally validate these predictions in a calcium imaging-based bioassay.
